Tag: IHL

Hallucinogens ASX depression post traumatic stress disorder PTSD psychedelic psychotherapy

With their mind-blowing medical potential, are hallucinogens the next ASX ‘pot stock’ equivalent?

The mere mention of magic mushrooms, ecstasy or ketamine is enough to send parents of teenagers into conniptions. But are these so-called party drugs poised to follow cannabis into the realm of a medi...
Incannex Healthcare ASX IHL sepsis associated acute respiratory distress syndrome SAARDS ARDS

Incannex Healthcare secures pre-IND meeting with US FDA to progress IHL-675A in treating SAARDS and ARDS

Incannex Healthcare (ASX: IHL) will confer with the United States Food and Drug Administration after the body granted a pre-investigational new drug meeting regarding progressing the company’s IHL-675...
Incannex Healthcare rheumatoid arthritis study results ASX IHL

Incannex Healthcare study results point to IHL-675A as a treatment option for rheumatoid arthritis

Positive results from an in vivo study model using Incannex Healthcare’s (ASX: IHL) lead candidate IHL-675A have triggered the launch of a sixth clinical program investigating the benefits of the drug...
Incannex Healthcare ASX IHL Monash University Trauma Group NFL sport concussion

Incannex Healthcare and Monash Trauma Group to undertake sports concussion study using model developed by the NFL

Incannex Healthcare (ASX: IHL) has revealed it will work with Monash Trauma Group on an “extensive” in vivo study evaluating the protective effect of IHL-216A in sports concussion. Monash Trauma Gr...
Incannex Healthcare Inflammatory Bowel Disease ASX IHL cannabis cannabidiol hydroxychloroquine

Incannex Healthcare’s drug candidate IHL-675A could become a multi-use medication

Incannex Healthcare (ASX: IHL) has been buoyed by the potential of its candidate IHL-675A to become a multi-use medication after receiving positive results from another pre-clinical in vivo trial into...
Incannex Healthcare ASX IHL Austrian clinic CBD oil COVID-19 Klagenfurt Clinic

Incannex Healthcare attracts interest as Austrian clinic uses CBD to treat COVID-19

News that an Austrian hospital using medical cannabis to treat patients with COVID-19 has yielded positive results is spurring investor interest in Incannex Healthcare (ASX: IHL), according to the Aus...
Incannex IHL ASX inflammatory lung conditions COPD asthma bronchitis in vivo

Incannex Healthcare study finds lead drug IHL-675A has ‘superior’ anti-inflammatory capabilities

Clinical stage pharmaceutical development company Incannex Healthcare (ASX: IHL) has received positive results from an additional in vivo study in assessing the anti-inflammatory capabilities of its l...
Incannex Healthcare IHL ASX quarter record sales therapeutic portfolio December 2020

Incannex Healthcare achieves another quarter of record sales, therapeutic portfolio advances

The December 2020 quarter heralded Incannex Healthcare’s (ASX: IHL) fifth consecutive period of record sales receipts, while it continued to advance its proprietary therapeutics for sleep apnoea, seps...
Incannex Healthcare IHL ASX first patients phase 2 obstructive sleep apnoea clinical trial

Incannex Healthcare recruits for IHL-42X obstructive sleep apnoea clinical trial

On a path to developing a suite of cannabinoid-based medicines aimed at remedying a range of debilitating conditions, pharmaceutical development company Incannex Healthcare (ASX: IHL) has recruited th...
Incannex Healthcare ASX IHL IHL-216A traumatic brain injury in vivo cannabidiol TBI

Pre-clinical research of Incannex Healthcare’s IHL-216A drug found it effective preventing traumatic brain injury

Incannex Healthcare (ASX: IHL) has revealed more positive in vivo research for its IHL-216A drug, this time regarding traumatic brain injury and has filed a patent application to cover this intellectu...
Incannex Healthcare ASX IHL Monash University psilocybin assisted psychotherapy anxiety disorder

Incannex Healthcare and Monash University to undertake ‘world first’ trial using psilocybin mushrooms to treat anxiety

Incannex Healthcare (ASX: IHL) has partnered with Monash University to undertake a “world first” clinical trial using psilocybin-assisted psychotherapy to treat generalised anxiety disorder. Accord...
Incannex Healthcare ASX IHL in vivo drug COVID-19 infection anti-inflammatory

Incannex Healthcare reveals positive in vivo results, will call Pre-IND meeting with FDA

Cannabinoid development company Incannex Healthcare (ASX: IHL) has unveiled the latest test results of its lead drug candidate IHL-675A, which show its anti-inflammatory potency make it an excellent c...
Incannex Healthcare trading halt study results FDA strategy ASX IHL

Incannex Healthcare enters trading halt ahead of study results and FDA strategy

Cannabinoid drug development company Incannex Healthcare (ASX: IHL) could be on the cusp of announcing a significant development in its mission to develop workable cannabinoid treatments for a range o...
Incannex Healthcare ASX IHL hydroxychloroquine cannabidiol inhibit inflammation SAARDS

Incannex lead drug candidate exhibits stronger anti-inflammatory action than CBD in preclinical studies

Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has received positive results from pre-clinical in vitro studies into the anti-inflammatory potency of its lead drug IHL-6...
Incannex ASX IHL medicinal cannabis oil pharmaceutical company Australia Special Access Scheme

Incannex achieves record medicinal cannabis oil sales as pure play pharmaceutical company

Incannex (ASX: IHL) has reported its highest quarterly sales for the September period – beating its previous June quarter record. For the three months ending September 2020, Incannex received $695,...
Incannex Healthcare IHL ASX cannabinoid Obstructive Sleep Apnoea clinical trial

Incannex receives ethics approval for novel cannabinoid in phase 2b obstructive sleep apnoea trial

Incannex Healthcare (ASX: IHL) has received ethics approval for a phase 2b clinical trial to study the therapeutic benefits of its lead drug IHL-42X on patients with obstructive sleep apnoea (OSA). ...
Incannex Healthcare ASX IHL in vitro results sepsis-associated acute respiratory disease drug studies

Incannex announces in vitro results from sepsis-associated acute respiratory disease drug studies

Clinical-stage cannabinoid development company Incannex Healthcare (ASX: IHL) has announced positive preliminary results on the anti-inflammatory activity of lead drug IHL-675A against sepsis-associat...
Incannex ASX IHL animal trial establish optimal dosage treating traumatic brain injuries

Incannex commences animal trial to establish optimal dosage of IHL-216A in treating traumatic brain injuries

Cannabinoid development company Incannex Healthcare (ASX: IHL) has commenced a pre-clinical animal trial investigating the neuroprotective capabilities of its lead candidate IHL-216A. The trial wil...
Incannex Healthcare ASX IHL COVID-19 sepsis-associated acute respiratory distress syndrome SAARDS study cannabis

Incannex reports positive results from animal study into CBD-based drug for ARDS resulting from COVID-19

After reporting amiable progress concerning its sleep apnoea drug IHL-42X just last week, cannabinoid drug development company Incannex Healthcare (ASX: IHL) has published positive results from its an...
Incannex Healthcare ASX IHL The Alfred Hospital CBD drug patients obstructive sleep apnoea

Incannex partners with The Alfred Hospital for clinical trial to study impact of cannabinoid drug on patients with obstructive sleep apn...

Clinical stage cannabinoid development company Incannex Healthcare (ASX: IHL) has partnered with The Alfred Hospital in Melbourne for a phase 2b dose finding crossover trial investigating the effect o...
Incannex Healthcare ASX IHL record sales cannabis oil CBD Cannagesia

Incannex Healthcare shifts from making an impression to setting sales records

Cannabinoid development company Incannex Healthcare (ASX: IHL) has published provisional performance figures for the past quarter, declaring a “record” three months with sales momentum expected to con...

RECENT POSTS

STOCK SUMMARY

FOLLOW US

HOT TOPICS

TRENDING POSTS